TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01931683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway (LMA)
Description: LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
Study: NCT00516178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fish oil emulsion
Description: 0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 3 infusions, perioperative or post-PTCA
Study: NCT02247141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subgam® (Human Normal Immunoglobulin Solution)
Study: NCT02980198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFN-Kinoid
Description: IM administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51
Description: adjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ISA 51
Description: adjuvant
Study: NCT00662415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mirror-box treatment
Description: 15 minutes daily for 4 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: observation
Description: observation
Study: NCT01570101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE Marked Sapheon Closure System
Description: CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting.
Study: NCT01629004

Intervention type: OTHER
Group type: OTHER
Intervention: FOBT kit
Description: Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
Study: NCT01854164

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HGE (hydrolyzed ginseng extract)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00830284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver
Description: Three types of maneuvers will be performed.~1. 6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~2. 6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~3. PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher.
Study: NCT04883541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga and meditation
Description: The pregnant women in the study group were given yoga and meditation classes, which included a total of twenty 10-week lessons, which were done by the researchers as 6-week birth preparation training, and with the onset of the birth action, birth processes were followed in the course of labour period yoga and meditation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Birth preparation training
Description: The control group was only given delivery preparation training for 6 weeks, and the birth processes were followed by routine follow-ups.
Study: NCT01840696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Vasodilator stress testing
Study: NCT03336749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory group
Description: The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Traditional task-specific training
Study: NCT03237741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference capsule GDC-0134
Description: Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference capsule GDC-0134
Description: Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference capsule GDC-0134
Description: Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference capsule GDC-0134
Description: Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
Study: NCT01629004

Intervention type: OTHER
Group type: OTHER
Intervention: FOBT kit
Description: Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Mailed invitation
Description: Mailed CRC screening invitation alone on behalf of family physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Mailed invitation
Description: Mailed CRC screening invitation alone on behalf of family physician.
Study: NCT00783744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: In the morning to target FBG ≤ 100 mg/dl
Study: NCT03237741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype capsule GDC-0134
Description: Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
Study: NCT00783744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 3 or 4 mg
Study: NCT03237741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype capsule GDC-0134
Description: Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype capsule GDC-0134
Description: Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prototype capsule GDC-0134
Description: Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
Study: NCT01330719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diseased periodontal treatment
Description: Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional periodontal treatment
Description: Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
Study: NCT00896389

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Salt loading
Description: Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide (HCTZ)
Description: We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
Study: NCT00543634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin/MPA
Description: 0.625 mg/2.5 mg X4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin/MPA
Description: 0.625 mg/5 mg X 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provera 10 mg
Description: 2.5 mg of MPA, 4 tablets dissoved in water
Study: NCT02064309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta-Air device for encapsulation of transplanted human islets
Study: NCT04092699

Intervention type: DEVICE
Group type: OTHER
Intervention: semiautomatic software
Description: semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.

Intervention type: DEVICE
Group type: OTHER
Intervention: semiautomatic software
Description: semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
Study: NCT00783744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At least 850 mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin monotherapy with premixed insulin NPH 30/70
Description: Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
Study: NCT05190393

Intervention type: PROCEDURE
Intervention: hemivertebra resection on convex side
Description: Patients were used hemivertebra resection procedure to treat congenital cervical scoliosis.

Intervention type: PROCEDURE
Intervention: concave distraction group
Description: Patients were used distraction and lateral opening procedure to treat congenital cervical scoliosis.
Study: NCT02034578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT01704417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
Study: NCT02908412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digital nerve block with bupivacaine
Description: The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
Study: NCT01704417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
Study: NCT00000457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion (Wellbutrin)
Description: 1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
Study: NCT03405987

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain analysis by CMR
Description: Strain analysis by CMR will be performed

Intervention type: DIAGNOSTIC_TEST
Intervention: Strain analysis by CMR
Description: Strain analysis by CMR will be performed
Study: NCT02188433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit immediately (QI) / cut down to quit (CDTQ)
Description: Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit immediately (QI) / cut down to quit (CDTQ)
Description: Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
Study: NCT03397264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT00674219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Namenda 10mg BID for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Namenda 10mg BID for 12 weeks
Study: NCT03192683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Providence Pedi Cast-Sling
Description: Custom made sling with readily available casting materials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular sling
Study: NCT03754491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One stage treatment for mild and moderate cholangitis with choledocholithiasis
Description: one stage of stone removal in mild or moderate cholangitis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One stage treatment for mild and moderate cholangitis with choledocholithiasis
Description: one stage of stone removal in mild or moderate cholangitis.
Study: NCT04351282

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for oligometastatic lesions will be assigned to those who got PR,SD after systemic treatment.
Study: NCT01783769

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low O.R. Traffic
Description: Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic.
Study: NCT02122094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Health Promotion Intervention
Description: The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
Study: NCT00744510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: 10 weekly sessions of 45 minutes each
Study: NCT02209779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03397264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT02209779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02596360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmodexane® 30mg
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
Study: NCT02727946

Intervention type: OTHER
Group type: OTHER
Intervention: optimal resuscitation
Description: optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
Study: NCT00194402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Slo-Niacin, atorvastatin
Description: Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Slo-Niacin, atorvastatin
Description: Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
Study: NCT03764774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3463251
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3463251
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01358929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to RO6807952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6807952
Description: Escalating subcutaneous dose
Study: NCT03171805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
Study: NCT02972905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 ELLIPTA DPI
Description: GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ELLIPTA DPI
Description: Placebo ELLIPTA DPI contains lactose
Study: NCT01707394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days